Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

From an old interview:

Question: Because of the uniqueness of Kevetrin, a variety of opportunities could be presented with regards to the human trials that are not normally available for many biotechs. Could you share your thoughts on the possibilities?

Leo: That is exactly true that we may have some significant advantages being that Kevetrin is a new class of chemistry in medicine. One of the single, most important facts is that we will be getting our target audience in Phase I; something that typically doesn’t happen. Phase I is generally for testing safety of the drug, but because we will be getting terminal cancer patients, it provides us with the potential to show efficacy. If that happens, many windows of opportunity open with regards to applying for priority review or FDA Fast Track status which can exponentially expedite the pace of trials and possibly move us into advanced stage trials in the mid-term. We are very optimistic about being able to replicate some of our pre-clinical trials that have demonstrated tumor growth delay and reduction in tumor volumes across a broad spectrum of strains of cancer and are excited to get into the clinical trials to see if our contentions are validated.

That was before Breakthrough Therapy Designation is available. So expect BTD for Kevetrin against several solid tumor types.